uniQure Investors File Class Action Lawsuit Over FDA Approval Delay
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy QURE?
Source: Globenewswire
- Lawsuit Background: uniQure N.V. is facing a class action lawsuit for failing to disclose the FDA approval delay of its drug AMT-130, with a deadline for lead plaintiff applications set for April 13, 2026, affecting investors who purchased shares between September 24 and October 31, 2025.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, over 49%, from $67.69 on October 31 to $34.29, significantly impacting investors' financial positions due to the FDA's rejection of its clinical trial data.
- Legal Accountability: uniQure and certain executives are charged with failing to disclose material information during the class period, violating federal securities laws, which could lead to severe legal repercussions for the company.
- Investor Rights: Investors wishing to participate in the lawsuit or learn about their legal rights can contact Kahn Swick & Foti LLC for legal support to recover economic losses incurred from the stock price drop.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 14.730
Low
33.00
Averages
49.88
High
70.00
Current: 14.730
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Investors File Class Action Lawsuit Over FDA Approval Delay
- Lawsuit Background: uniQure N.V. is facing a class action lawsuit for failing to disclose the FDA approval delay of its drug AMT-130, with a deadline for lead plaintiff applications set for April 13, 2026, affecting investors who purchased shares between September 24 and October 31, 2025.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, over 49%, from $67.69 on October 31 to $34.29, significantly impacting investors' financial positions due to the FDA's rejection of its clinical trial data.
- Legal Accountability: uniQure and certain executives are charged with failing to disclose material information during the class period, violating federal securities laws, which could lead to severe legal repercussions for the company.
- Investor Rights: Investors wishing to participate in the lawsuit or learn about their legal rights can contact Kahn Swick & Foti LLC for legal support to recover economic losses incurred from the stock price drop.
See More
uniQure Faces Update in Securities Class Action Lawsuit
- FDA Allegations: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Ethical Controversy: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that the agency did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially affecting the company's compliance in clinical trials.
- Legal Action: The pending securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, leading to a 49% stock drop on November 3, 2025, reflecting significant failures in information disclosure.
- Critical Deadline: Investors must apply by April 13, 2026, to be appointed as Lead Plaintiff in the class action; failure to act promptly may result in lost opportunities for compensation, further impacting their investment returns.
See More
Notice to Shareholders of uniQure N.V. Regarding Class Action
- Lawsuit Background: The Gross Law Firm has issued a notice to shareholders of uniQure N.V. (NASDAQ:QURE), encouraging those who purchased shares during the class period from September 24, 2025, to October 31, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations: The complaint alleges that during the class period, uniQure made materially false and/or misleading statements, failing to disclose that the design of its pivotal study was not fully FDA approved and that it might need to delay its Biologics License Application (BLA) timeline for additional studies.
- Participation Requirements: Shareholders must register by April 13, 2026, to participate in the class action, and upon registration, they will receive status updates throughout the lifecycle of the case, ensuring they remain informed about developments.
- Law Firm's Strength: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights and ensuring companies adhere to responsible business practices, seeking recovery for investors who suffered losses due to misleading statements.
See More
uniQure Faces Class Action Lawsuit Amid FDA Criticism
- FDA Allegations: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Class Action Update: Hagens Berman is investigating a securities class action lawsuit against uniQure for failing to disclose critical interactions with the FDA during the class period from September 24 to October 31, 2025, potentially impacting investor decisions.
- Critical Deadline: Investors have until April 13, 2026, to apply as Lead Plaintiff in the class action; failure to act promptly may result in lost claims and exacerbate investor losses, highlighting the urgency of the situation.
- Whistleblower Program: Whistleblowers with non-public information about uniQure can benefit from the SEC Whistleblower program, potentially receiving rewards of up to 30% of any successful recovery, incentivizing insiders to provide crucial information to aid the investigation.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- Stock Price Plunge: On November 3, 2025, uniQure revealed uncertainties regarding the BLA submission timeline for its AMT-130 drug, causing its stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting investor disappointment in the company's prospects.
- False Statements Allegations: The lawsuit alleges that uniQure made misleading statements regarding its clinical trials and FDA submissions, failing to disclose critical adverse information that may have led investors to make uninformed decisions, thereby affecting their investment returns.
- Investor Action Recommendations: Affected uniQure investors are advised to apply by April 13, 2026, to serve as lead plaintiffs in the class action, emphasizing the importance of corporate governance and transparency in protecting investor interests.
See More
uniQure Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against uniQure N.V., seeking damages for investors who purchased the company's securities between September 24, 2025, and October 31, 2025, reflecting strong investor response to potential violations.
- Detailed Allegations: The complaint alleges that uniQure's executives made materially false statements regarding the company's business and operations, failing to disclose critical facts related to FDA approval, which could lead to misjudgments about the company's prospects and impact market confidence.
- BLA Submission Delay Risk: The lawsuit highlights that despite purportedly successful results from the Pivotal Study, uniQure may need to delay its Biologics License Application (BLA) timeline due to the necessity for additional studies, with this omission potentially causing significant losses for investors.
- Investor Recovery Opportunity: Affected investors must apply by April 13, 2026, to be appointed as lead plaintiff to participate in potential recovery, indicating that legal avenues provide investors with a chance to recover losses and enhance oversight of corporate governance.
See More
uniQure Investors File Class Action Lawsuit Over FDA Approval Delay
- Lawsuit Background: uniQure N.V. is facing a class action lawsuit for failing to disclose the FDA approval delay of its drug AMT-130, with a deadline for lead plaintiff applications set for April 13, 2026, affecting investors who purchased shares between September 24 and October 31, 2025.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, over 49%, from $67.69 on October 31 to $34.29, significantly impacting investors' financial positions due to the FDA's rejection of its clinical trial data.
- Legal Accountability: uniQure and certain executives are charged with failing to disclose material information during the class period, violating federal securities laws, which could lead to severe legal repercussions for the company.
- Investor Rights: Investors wishing to participate in the lawsuit or learn about their legal rights can contact Kahn Swick & Foti LLC for legal support to recover economic losses incurred from the stock price drop.
See More
uniQure Faces Update in Securities Class Action Lawsuit
- FDA Allegations: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Ethical Controversy: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that the agency did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially affecting the company's compliance in clinical trials.
- Legal Action: The pending securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, leading to a 49% stock drop on November 3, 2025, reflecting significant failures in information disclosure.
- Critical Deadline: Investors must apply by April 13, 2026, to be appointed as Lead Plaintiff in the class action; failure to act promptly may result in lost opportunities for compensation, further impacting their investment returns.
See More
Notice to Shareholders of uniQure N.V. Regarding Class Action
- Lawsuit Background: The Gross Law Firm has issued a notice to shareholders of uniQure N.V. (NASDAQ:QURE), encouraging those who purchased shares during the class period from September 24, 2025, to October 31, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations: The complaint alleges that during the class period, uniQure made materially false and/or misleading statements, failing to disclose that the design of its pivotal study was not fully FDA approved and that it might need to delay its Biologics License Application (BLA) timeline for additional studies.
- Participation Requirements: Shareholders must register by April 13, 2026, to participate in the class action, and upon registration, they will receive status updates throughout the lifecycle of the case, ensuring they remain informed about developments.
- Law Firm's Strength: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights and ensuring companies adhere to responsible business practices, seeking recovery for investors who suffered losses due to misleading statements.
See More
uniQure Faces Class Action Lawsuit Amid FDA Criticism
- FDA Allegations: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Class Action Update: Hagens Berman is investigating a securities class action lawsuit against uniQure for failing to disclose critical interactions with the FDA during the class period from September 24 to October 31, 2025, potentially impacting investor decisions.
- Critical Deadline: Investors have until April 13, 2026, to apply as Lead Plaintiff in the class action; failure to act promptly may result in lost claims and exacerbate investor losses, highlighting the urgency of the situation.
- Whistleblower Program: Whistleblowers with non-public information about uniQure can benefit from the SEC Whistleblower program, potentially receiving rewards of up to 30% of any successful recovery, incentivizing insiders to provide crucial information to aid the investigation.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- Stock Price Plunge: On November 3, 2025, uniQure revealed uncertainties regarding the BLA submission timeline for its AMT-130 drug, causing its stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting investor disappointment in the company's prospects.
- False Statements Allegations: The lawsuit alleges that uniQure made misleading statements regarding its clinical trials and FDA submissions, failing to disclose critical adverse information that may have led investors to make uninformed decisions, thereby affecting their investment returns.
- Investor Action Recommendations: Affected uniQure investors are advised to apply by April 13, 2026, to serve as lead plaintiffs in the class action, emphasizing the importance of corporate governance and transparency in protecting investor interests.
See More
uniQure Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against uniQure N.V., seeking damages for investors who purchased the company's securities between September 24, 2025, and October 31, 2025, reflecting strong investor response to potential violations.
- Detailed Allegations: The complaint alleges that uniQure's executives made materially false statements regarding the company's business and operations, failing to disclose critical facts related to FDA approval, which could lead to misjudgments about the company's prospects and impact market confidence.
- BLA Submission Delay Risk: The lawsuit highlights that despite purportedly successful results from the Pivotal Study, uniQure may need to delay its Biologics License Application (BLA) timeline due to the necessity for additional studies, with this omission potentially causing significant losses for investors.
- Investor Recovery Opportunity: Affected investors must apply by April 13, 2026, to be appointed as lead plaintiff to participate in potential recovery, indicating that legal avenues provide investors with a chance to recover losses and enhance oversight of corporate governance.
See More
